Entering text into the input field will update the search result below

Harpoon Therapeutics wins FDA’s Orphan Drug Designation for lung cancer therapy

Mar. 07, 2022 7:52 AM ETHarpoon Therapeutics, Inc. (HARP)By: Dulan Lokuwithana, SA News Editor

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • The clinical-stage immunotherapy company, Harpoon Therapeutics (NASDAQ:HARP) announced on Monday that the U.S. Food and Drug Administration (FDA) granted the Orphan Drug Designation for its investigational product, HPN328, for the treatment in small cell lung cancer (SCLC).

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.